Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.

Published on Mar 1, 2021in Journal of Experimental & Clinical Cancer Research7.068
· DOI :10.1186/S13046-021-01886-X
Valentina Zuco25
Estimated H-index: 25
Sandro Pasquali28
Estimated H-index: 28
+ 14 AuthorsNadia Zaffaroni66
Estimated H-index: 66
Background Dedifferentiated liposarcoma (DDLPS), a tumor that lacks effective treatment strategies and is associated with poor outcomes, expresses amplified MDM2 in the presence of wild-type p53. MDM2 ubiquitination of p53 facilitates its XPO1-mediated nuclear export, thus limiting p53 tumor suppressor functions. Consequently, nuclear export is a rational target in DDLPS. We directly compared the antitumor activity of the first-in class XPO1 inhibitor selinexor and doxorubicin, the standard front-line therapy in sarcomas, in DDLPS patient-derived xenografts (PDXs) and primary cell lines. Methods Drug activity was assessed in three PDXs (and two corresponding cell lines) established from the dedifferentiated component of primary untreated retroperitoneal DDLPS with myogenic (N = 2) and rhabdomyoblastic (N = 1) differentiation from patients who underwent surgery. These models were marked by amplification of MDM2, CDK4 and HMGA2 genes. Results Selinexor was moderately active in the three PDXs but achieved greater tumor response compared to doxorubicin (maximum tumor volume inhibition: 46-80 % vs. 37-60 %). The PDX harboring rhabdomyoblastic dedifferentiation showed the highest sensitivity to both agents. PDX response to selinexor and doxorubicin was not associated with the extent of MDM2 and CDK4 gene amplification. Interestingly, the most chemosensitive PDX model showed the lowest extent of HMGA2 amplification. Selinexor was also more efficient than doxorubicinin in inducing an apoptotic response in PDXs and cell lines. Consistently, an increased nuclear accumulation of p53 was seen in all selinexor-treated models. In addition, a time-dependent decrease of survivin expression, with an almost complete abrogation of the cytoplasmic anti-apoptotic pool of this protein, was observed as a consequence of the decreased acetylation/activation of STAT3 and the increased ubiquitination of nuclear survivin. Conclusions Selinexor showed a moderate antitumor activity in three DDLPS PDXs, which was, however, consistently higher than doxorubicin across all different models regardless the extent of MDM2 amplification and the histological differentiation. The depletion of survivin protein seems to significantly contribute to the induction of apoptosis through which selinexor exerts its antitumor activity.
#1Jeremy Lewin (Princess Margaret Cancer Centre)H-Index: 13
#2Eoghan Ruadh Malone (Princess Margaret Cancer Centre)H-Index: 3
Last. Albiruni Ryan Abdul Razak (Princess Margaret Cancer Centre)H-Index: 35
view all 8 authors...
Abstract Background Selinexor is a first-in-class selective inhibitor of nuclear export (SINE) compound with single-agent activity in soft tissue sarcoma (STS). The study’s aim was to determine the safety and efficacy of selinexor in combination with doxorubicin in patients with locally advanced/metastatic STS. Methods This phase 1b study used a mTPI design. Patients received selinexor at either 60 or 80 mg weekly PO plus doxorubicin (75 mg/m2 IV q21 days). Patients with clinical benefit (define...
2 CitationsSource
#1Kyoko Yamashita (JFCR: Japanese Foundation for Cancer Research)H-Index: 10
#2Kenichi Kohashi (Kyushu University)H-Index: 27
Last. Yoshinao Oda (Kyushu University)H-Index: 71
view all 8 authors...
Dedifferentiated liposarcoma (DDLPS) is a relatively common soft tissue sarcoma that results from the progression of well-differentiated liposarcoma (WDLPS). This study aimed to investigate the progression process and to clarify the pathological and genetic factors related to poor prognosis in DDLPS. In 32 DDLPS cases and five WDLPS cases, genetic factors were analyzed by custom comparative genomic hybridization (CGH) array, which was designed to densely cover gene regions known to be frequently...
1 CitationsSource
#1Silvia MartiniH-Index: 3
#2Mariangela FiginiH-Index: 26
Last. Alessandro SattaH-Index: 4
view all 12 authors...
Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific antibodies (BsAbs), able to redirect T cells against tumors, has shown promising results. In particular, a BsAb that uses TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) as a target was constructed and demonstrated good results in redirec...
2 CitationsSource
#1Silvia StacchiottiH-Index: 61
Last. Hans GelderblomH-Index: 89
view all 10 authors...
1 CitationsSource
#1Zhubin Gahvari (UW: University of Wisconsin-Madison)H-Index: 4
#2Amanda Parkes (UW: University of Wisconsin-Madison)H-Index: 6
Over the last several years, the systemic treatment landscape for dedifferentiated liposarcoma (DDLPS) has notably expanded. Historically, systemic therapy options have been limited to cytotoxic chemotherapy agents, including doxorubicin, ifosfamide, gemcitabine, and docetaxel, that were shown to have efficacy in unselected populations of patients with soft tissue sarcomas. More recently, however, there have been phase II and III trials establishing clinical benefit of the cytotoxic agents trabe...
7 CitationsSource
#1Ali Amin-Mansour (Broad Institute)H-Index: 12
#2Suzanne George (Harvard University)H-Index: 63
Last. Andrew J. Wagner (Harvard University)H-Index: 52
view all 19 authors...
Purpose: Leiomyosarcoma (LMS) and liposarcoma (LPS) are common subtypes of soft tissue sarcoma (STS). Patients with metastatic LMS or dedifferentiated LPS (DDLPS) typically have worse outcomes compared to localized LMS or well-differentiated LPS (WDLPS). A better understanding of genetic changes between primary/metastatic LMS and between WDLPS/DDLPS may provide insight into their genetic evolution. Experimental Design: We interrogated whole exome sequencing (WES) from "trios" of normal tissue, p...
7 CitationsSource
#1Shukun Han (PRC: China Medical University (PRC))H-Index: 1
#2Bing HanH-Index: 1
Last. Du Sun (PRC: China Medical University (PRC))H-Index: 1
view all 4 authors...
ABSTRACTAt present, some researches have revealed the participation of long noncoding RNAs (lncRNAs) in liver cancer, but few of them have mentioned the role of CRNDE in drug resistance of liver ca...
8 CitationsSource
#1Jin-Tian Miao (HMU: Harbin Medical University)H-Index: 1
#2Jian-Hua Gao (HMU: Harbin Medical University)H-Index: 1
Last. Ge Lou (HMU: Harbin Medical University)H-Index: 1
view all 6 authors...
This paper tried to explore ANRIL expression in ovarian cancer and how it affects cisplatin-sensitivity of ovarian cancer cells via regulation of let-7a/high-mobility group protein A2 (HMGA2) axis. qRT-PCR was used to detect ANRIL and let-7a levels in ovarian cancer tissues and cell lines (SKOV3 and SKOV3/DDP). Then cells were randomly assigned into Blank, negative control siRNA, ANRIL siRNA, let-7a inhibitor, and ANRIL siRNA+let-7a-inhibitor groups. CCK-8 assay was applied for assessing cell vi...
13 CitationsSource
#1Han-Qing Zhu (SJTU: Shanghai Jiao Tong University)H-Index: 2
#2Chao Zhang (SJTU: Shanghai Jiao Tong University)H-Index: 4
Last. Feng-Hou Gao (SJTU: Shanghai Jiao Tong University)H-Index: 14
view all 10 authors...
: Oridonin could induce NB (neuroblastoma) cells growth inhibition by inducing apoptosis and cell cycle arrest, and the molecular mechanisms behind the effects deserve to be further explored. Here, oridonin was confirmed to cause the reactivation of p53 (cellular tumor antigen p53) to promote the expression of a series of apoptosis- and cell cycle arrest-related proteins for the biological effects. During the process, oridonin relied on the caspase activation to cleave p53-induced Mdm2 (E3 ubiqu...
2 CitationsSource
#1Silvia StacchiottiH-Index: 61
#2Valentina ZucoH-Index: 25
Last. Nadia ZaffaroniH-Index: 66
view all 21 authors...
Epithelioid sarcoma (ES) is a rare mesenchymal malignancy marked by SMARCB1/INI1 deficiency. Retrospective clinical data report on the activity of anthracycline- and gemcitabine-based regimens. EZH2 inhibitors are currently being tested in clinical trials. Since comparisons of these agents are unlikely to be prospectively evaluated in the clinics, we took advantage of an INI1-deficient proximal-type ES patient-derived xenograft (PDX ES-1) to comparatively assess its preclinical antitumor activit...
6 CitationsSource
Cited By0